Physician profile
Ryan Kaufman
NPI 1205452059
$1,687.94
in general payments reported to CMS, 2019-2025
18 companies · $711 in 2025
The $711 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $359 · 2024: $618 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,687.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $380.78 | 2023-2025 | |
| Novo Nordisk INC | $336.05 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $180.68 | 2023-2025 | |
| Lilly USA, LLC | $143.37 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $93.09 | 2023-2025 | Breztri, Flumist Quadrivalent, Airsupra |
| Exact Sciences Corporation | $92.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.17 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $78.31 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Tempus Ai, INC | $68.70 | 2024 | |
| Astellas Pharma US INC | $53.70 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.26 | 2024-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $32.18 | 2025 | Voquezna |
| Alkermes, INC. | $23.58 | 2025 | Aristada, Lybalvi |
| Dynavax Technologies Corporation | $20.00 | 2023 | Heplisav-B |
| Axsome Therapeutics, INC. | $17.83 | 2025 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $15.41 | 2023 | Quviviq |
| Halozyme INC | $13.56 | 2023 | |
| Sanofi Pasteur INC. | $12.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Kaufman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.